Low-dose Adriamycin remission maintenance therapy for pediatric solid tumors.
A low-dose maintenance schedule of Adriamycin was evaluated in six children whose metastatic solid tumors regressed following toxic induction therapy with Adriamycin. Three of these children are now disease-free more than one year following discontinuation of therapy. Adriamycin can be given on a low-dose maintenance schedule free from alopecia, fever, stomatitis, myelosuppression and recognizable cardiomyopathy. Further studies of similar schedules are warranted.
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004317:Doxorubicin / Q000008:administration & dosage* / Q000627:therapeutic use; D005153:Facial Neoplasms / Q000188:drug therapy; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D007223:Infant; D008297:Male; D009362:Neoplasm Metastasis; D009442:Neurilemmoma / Q000188:drug therapy; D009447:Neuroblastoma / Q000188:drug therapy; D012208:Rhabdomyosarcoma / Q000188:drug therapy; D012447:Sacrum; D013125:Spinal Neoplasms / Q000188:drug therapy; D013724:Teratoma / Q000188:drug therapy
D000970:Antineoplastic Agents; D004317:Doxorubicin